Novel Thiazole-Fused [4,5-<i>g</i>] or [5,4-<i>g</i>]Quinazolin-8-ones and Their Quinazoline Analogues: Synthesis and Biological Evaluation

• Main Authors: Nathan Broudic (Author), Alexandra Pacheco-Benichou (Author), Cécile Corbière (Author), Blandine Baratte (Author), Thomas Robert (Author), Stéphane Bach (Author), Hélène Solhi (Author), Rémy Le Guével (Author), Corinne Fruit (Author), Thierry Besson (Author)
• Format: Book
• Published: MDPI AG, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<b>Background/Objectives:</b> In connection with previous work on V-shaped polycyclic thiazolo[5,4-<i>f</i>]quinazolin-9-one and [5,4-<i>f</i>]quinazoline derivatives that can modulate the activity of various kinases, the synthesis of straight thiazole-fused [4,5-<i>g</i>] or [5,4-<i>g</i>]quinazolin-8-ones and quinazoline derivatives hitherto undescribed was envisioned. <b>Methods:</b> An innovative protocol allowed to obtain the target structures. The synthesis of inverted thiazolo[4,5-<i>h</i>] and [5,4-<i>h</i>]quinazolin-8-one derivatives was also explored with the aim of comparing biological results. The compounds obtained were tested against a representative panel of eight mammalian protein kinases of human origin: CDK9/CyclinT, Haspin, Pim-1, GSK-3β, CK-1ε, JAK3, CLK1 and DYRK1A. <b>Results and Conclusions:</b> The results obtained show that the novel linear thiazoloquinazolines are not kinase inhibitors. The cytotoxicity of these newly synthesized compounds was assessed against seven representative tumor cell lines (human cancers: Huh7-D12, Caco-2, HCT-116, MCF-7, MDA-MB-231, MDA-MB-468 and PC-3). The majority of these novel molecules proved capable of inhibiting the growth of the tested cells. The 7-Benzyl-8-oxo-7,8-dihydrothiazolo[5,4-<i>g</i>]quinazolinones <b>5b</b> and <b>6b</b> are the most potent, with IC₅₀ values in the micromolar range. None of these compounds showed toxicity against normal cells. A larger program of investigations will be launched to investigate the real potential interest of such compounds in anticancer applications.

Item Description

10.3390/ph17111452
1424-8247